"We are excited to establish the agreement with GSK, a global biopharma company. It reflects the growing recognition of our R&D capabilities. This agreement will solidify a robust foundation for ...

-- "ADX-324, A Semi-Annual SC Investigational siRNA Targeting Prekallikrein for HAE Attack Prevention" (Poster number: 089) on Friday, February 27, 2026 from 2:45 -- 3:45 pm EST in the Pennsylvania ...

Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepatic ...

Emerging modalities such as self-amplifying and circular RNA, expanding oncology and rare-disease applications, and scalable manufacturing are creating high-growth investment avenues, supported by ...

Chinese biotech Frontier Biotechnologies announced on Tuesday an exclusive licensing agreement worth up to $1B with GSK (GSK) to jointly advance a treatment class known as small interfering RNA ...

The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...

Please provide your email address to receive an email when new articles are posted on . In this video, Yancy, a professor and chief of cardiology at Northwestern University Feinberg School of Medicine ...

Please provide your email address to receive an email when new articles are posted on . Two small interfering RNA therapies lowered triglyceride levels in patients with mixed hyperlipidemia at 24 ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...

For the first time, a drug to treat adult patients with familial chylomicronemia syndrome (FCS), a severe and rare condition that leads to extremely high levels of blood fats called triglycerides, has ...